Cytokinetics CYTK Increase Decrease In Operating Lease Liabilities
Increase Decrease In Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept cytk:IncreaseDecreaseInOperatingLeaseLiabilities.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's increase decrease in operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's increase decrease in operating lease liabilities?
- Cytokinetics (CYTK) reported increase decrease in operating lease liabilities of -$1.04M in Q1 2026.
- How has Cytokinetics's increase decrease in operating lease liabilities changed year-over-year?
- Cytokinetics's increase decrease in operating lease liabilities increased by 51.5% year-over-year, from -$2.14M to -$1.04M.
- What is the long-term trend for Cytokinetics's increase decrease in operating lease liabilities?
- Over 4 years (2021 to 2025), Cytokinetics's increase decrease in operating lease liabilities has grown at a -29.3% compound annual growth rate (CAGR), from $43.47M to -$10.84M.
- What does increase decrease in operating lease liabilities mean?
- The net change in the company's total operating lease obligations.
- How do you interpret increase decrease in operating lease liabilities?
- Changes reflect the expansion or contraction of the company's physical footprint and lease commitments.
- How does increase decrease in operating lease liabilities compare across companies?
- Standardized across all companies reporting under IFRS 16 or ASC 842.